doxycycline + prednisolone + streptomycin

This is a combination therapy consisting of three active pharmaceutical ingredients: - **Doxycycline** is a broad-spectrum tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, thereby preventing the addition of amino acids to growing peptide chains. It is effective against a wide range of gram-positive and gram-negative bacteria and has additional anti-inflammatory properties. - **Prednisolone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive effects. It acts by modulating gene expression after binding to the glucocorticoid receptor, leading to decreased production of pro-inflammatory cytokines and mediators. - **Streptomycin** is an aminoglycoside antibiotic that binds irreversibly to the 30S subunit of bacterial ribosomes, causing misreading of mRNA and inhibition of protein synthesis, primarily effective against aerobic gram-negative bacteria. The combination doxycycline + streptomycin is considered first-line therapy for brucellosis due to their synergistic antibacterial activity[2][8]. Prednisolone may be added in certain clinical scenarios where inflammation needs suppression (e.g., severe infection with significant inflammatory response), though this specific triple combination does not have widespread standard use or unique brand name. Each component addresses different aspects—doxycycline and streptomycin target infection; prednisolone controls inflammation.